A study identifies familial Alzheimer’s mutations disrupting exosome release from brain cells, which may impair neurotrophic support and contribute to disease progression. Concurrently, Remynd’s agent targeting calcium homeostasis demonstrates efficacy in reducing tau pathology and improving cognition. Collectively, these insights deepen knowledge of Alzheimer’s pathophysiology and highlight emerging therapeutic targets within cellular communication and ion channel regulation.